347 related articles for article (PubMed ID: 21590771)
21. ARID1A is a useful marker of malignancy in peritoneal washings for endometrial carcinoma.
Nagymanyoki Z; Mutter GL; Hornick JL; Cibas ES
Cancer Cytopathol; 2015 Apr; 123(4):253-7. PubMed ID: 25557364
[TBL] [Abstract][Full Text] [Related]
22. Loss of ARID1A/BAF250a expression in ovarian endometriosis and clear cell carcinoma.
Xiao W; Awadallah A; Xin W
Int J Clin Exp Pathol; 2012; 5(7):642-50. PubMed ID: 22977660
[TBL] [Abstract][Full Text] [Related]
23. Clinicopathologic analysis of loss of AT-rich interactive domain 1A expression in endometrial cancer.
Rahman M; Nakayama K; Rahman MT; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Miyazaki K
Hum Pathol; 2013 Jan; 44(1):103-9. PubMed ID: 22939958
[TBL] [Abstract][Full Text] [Related]
24. Mammaglobin expression in the female genital tract: immunohistochemical analysis in benign and neoplastic endocervix and endometrium.
Onuma K; Dabbs DJ; Bhargava R
Int J Gynecol Pathol; 2008 Jul; 27(3):418-25. PubMed ID: 18580321
[TBL] [Abstract][Full Text] [Related]
25. Expression pattern of osteopontin in endometrial carcinoma: correlation with expression of the adhesion molecule CEACAM1.
Briese J; Schulte HM; Bamberger CM; Löning T; Bamberger AM
Int J Gynecol Pathol; 2006 Apr; 25(2):161-9. PubMed ID: 16633066
[TBL] [Abstract][Full Text] [Related]
26. beta- Catenin mutations and aberrant nuclear expression during endometrial tumorigenesis.
Saegusa M; Hashimura M; Yoshida T; Okayasu I
Br J Cancer; 2001 Jan; 84(2):209-17. PubMed ID: 11161379
[TBL] [Abstract][Full Text] [Related]
27. [Dualistic model of molecular pathogenesis in endometrial carcinoma].
Lax SF
Zentralbl Gynakol; 2002 Jan; 124(1):10-6. PubMed ID: 11873308
[TBL] [Abstract][Full Text] [Related]
28. The selective expression of ret finger protein in endometrial cancer: can RFP be a marker of serous carcinomas?
Tezel GG; Ordulu Z; Hımmetoğlu C; Usubütün A
Turk Patoloji Derg; 2012; 28(3):213-9. PubMed ID: 23011823
[TBL] [Abstract][Full Text] [Related]
29. Increased expression of the adult stem cell marker Musashi-1 in endometriosis and endometrial carcinoma.
Götte M; Wolf M; Staebler A; Buchweitz O; Kelsch R; Schüring AN; Kiesel L
J Pathol; 2008 Jul; 215(3):317-29. PubMed ID: 18473332
[TBL] [Abstract][Full Text] [Related]
30. Thyroid transcription factor-1 expression in endometrial and endocervical adenocarcinomas.
Siami K; McCluggage WG; Ordonez NG; Euscher ED; Malpica A; Sneige N; Silva EG; Deavers MT
Am J Surg Pathol; 2007 Nov; 31(11):1759-63. PubMed ID: 18059234
[TBL] [Abstract][Full Text] [Related]
31. [Expression of annexin I in different histological types of carcinomas].
Xue LY; Teng LH; Zou SM; Ren LQ; Zheng S; Luo W; Bi R; Lü N
Zhonghua Zhong Liu Za Zhi; 2007 Jun; 29(6):444-8. PubMed ID: 17974280
[TBL] [Abstract][Full Text] [Related]
32. IMP2 expression distinguishes endometrioid from serous endometrial adenocarcinomas.
Zhang L; Liu Y; Hao S; Woda BA; Lu D
Am J Surg Pathol; 2011 Jun; 35(6):868-72. PubMed ID: 21566514
[TBL] [Abstract][Full Text] [Related]
33. Molecular analysis of endometrial hyperplasia in HNPCC-suspicious patients may predict progression to endometrial carcinoma.
Sutter C; Dallenbach-Hellweg G; Schmidt D; Baehring J; Bielau S; von Knebel Doeberitz M; Gebert J
Int J Gynecol Pathol; 2004 Jan; 23(1):18-25. PubMed ID: 14668545
[TBL] [Abstract][Full Text] [Related]
34. Loss of ARID1A/BAF250a-expression in endometriosis: a biomarker for risk of carcinogenic transformation?
Samartzis EP; Samartzis N; Noske A; Fedier A; Caduff R; Dedes KJ; Fink D; Imesch P
Mod Pathol; 2012 Jun; 25(6):885-92. PubMed ID: 22301703
[TBL] [Abstract][Full Text] [Related]
35. From Krukenberg to today: the ever present problems posed by metastatic tumors in the ovary. Part II.
Young RH
Adv Anat Pathol; 2007 May; 14(3):149-77. PubMed ID: 17452813
[TBL] [Abstract][Full Text] [Related]
36. [Endometrial carcinoma and precursor lesions].
Djordjević B; Stanojević Z
Srp Arh Celok Lek; 2007; 135(3-4):230-4. PubMed ID: 17642468
[TBL] [Abstract][Full Text] [Related]
37. Apoptosis and the expression of Bcl-2 and Bax in patients with endometrioid, clear cell, and serous carcinomas of the uterine endometrium.
Kokawa K; Shikone T; Otani T; Nishiyama R; Ishii Y; Yagi S; Yamoto M
Gynecol Oncol; 2001 May; 81(2):178-83. PubMed ID: 11330946
[TBL] [Abstract][Full Text] [Related]
38. ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas.
Werner HM; Berg A; Wik E; Birkeland E; Krakstad C; Kusonmano K; Petersen K; Kalland KH; Oyan AM; Akslen LA; Trovik J; Salvesen HB
Mod Pathol; 2013 Mar; 26(3):428-34. PubMed ID: 23080032
[TBL] [Abstract][Full Text] [Related]
39. DCC genetic alterations and expression in endometrial carcinoma.
Ronnett BM; Burks RT; Cho KR; Hedrick L
Mod Pathol; 1997 Jan; 10(1):38-46. PubMed ID: 9021725
[TBL] [Abstract][Full Text] [Related]
40. (Partial) Loss of BAF250a (ARID1A) in rectovaginal deep-infiltrating endometriosis, endometriomas and involved pelvic sentinel lymph nodes.
Borrelli GM; Abrão MS; Taube ET; Darb-Esfahani S; Köhler C; Chiantera V; Mechsner S
Mol Hum Reprod; 2016 May; 22(5):329-37. PubMed ID: 26832958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
